GlassScriptPhysician profile
David G Morales
NPI 1265468326
$1,749.72
in general payments reported to CMS, 2019-2025
22 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $122 · 2021: $302 · 2022: $339 · 2023: $194 · 2024: $257 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $292.30 | 2019-2021 | |
| Abbvie INC. | $275.91 | 2021-2023 | |
| Abbott Laboratories | $201.54 | 2021-2024 | Epic |
| Pfizer INC. | $170.94 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $144.25 | 2019-2024 | |
| Novo Nordisk INC | $143.14 | 2019-2023 | Ozempic, Rybelsus |
| Imperative Care, INC | $81.73 | 2025 | Symphony Catheter |
| Allergan, INC. | $64.65 | 2019-2020 | |
| Lilly USA, LLC | $53.87 | 2019-2021 | |
| Amgen INC. | $48.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $43.41 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Astrazeneca Pharmaceuticals LP | $36.58 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $35.49 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $23.95 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $23.19 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $18.64 | 2019 | |
| Exact Sciences Corporation | $17.99 | 2023 | Cologuard Collection Kit |
| Nestle Healthcare Nutrition INC. | $16.88 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.56 | 2019 | |
| Mylan Specialty L.P. | $13.32 | 2019 | |
| Esperion Therapeutics, INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.